4.6 Article

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

期刊

CANCER IMMUNOLOGY RESEARCH
卷 7, 期 9, 页码 1472-1484

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-18-0841

关键词

-

资金

  1. Danish Council for Independent Research [DFF-1331-00095B]
  2. Danish Cancer Society [R72-A4396-13-S2]
  3. Training Network for the Immunotherapy of Cancer - EU (IMMUTRAIN
  4. H2020 grant) [641549]
  5. Danielsen Foundation
  6. Axel Musfeldts fond
  7. Else og Mogens Wedell-Wedellsborg Fond
  8. AP Moller Fonden
  9. Den Bohmske Fond
  10. Dagmar Marshalls Fond

向作者/读者索取更多资源

The TAM family of receptor tyrosine kinases TYRO3, AXL, and MERTK) is known to be expressed on antigen-presenting cells and function as oncogenic drivers and as inhibitors of inflammatory responses. Both human and mouse CD8(+) T cells are thought to be negative for TAM receptor expression. In this study, we show that T-cell receptor TCR)-activated human primary CD8(+) T cells expressed MERTK and the ligand PROS1 from day 2 postactivation. PROS1-mediated MERTK signaling served as a late costimulatory signal, increasing proliferation and secretion of effector and memory-associated cytokines. Knockdown and inhibition studies confirmed that this costimulatory effect was mediated through MERTK. Transcriptomic and metabolic analyses of PROS1-blocked CD8(+) T cells demonstrated a role of the PROS1-MERTK axis in differentiation of memory CD8(+) T cells. Finally, using tumor-infiltrating lymphocytes TIL) from melanoma patients, we show that MERTK signaling on T cells improved TIL expansion and TIL-mediated autologous cancer cell killing. We conclude that MERTK serves as a late costimulatory signal for CD8(+) T cells. Identification of this costimulatory function of MERTK on human CD8(+) T cells suggests caution in the development of MERTK inhibitors for hematologic or solid cancer treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据